Sino Biopharm

Sino Biopharmaceutical Co., Ltd. and its subsidiaries form a leading innovative research and R&D-driven pharmaceutical group in China, covering the entire industry chain including pharmaceutical R&D platforms, intelligent manufacturing, and a robust sales system. The product portfolio includes a variety of biologics and chemical drugs, with a strong presence in four major therapeutic areas: oncology, liver diseases, respiratory conditions, and surgery/pain management. The company was listed on the Hong Kong Stock Exchange in 2000, became a constituent of the MSCI Global Standard Index's China Index in 2013, joined the Hang Seng Index constituents in 2018, entered the Hang Seng China Enterprises Index constituents in 2019, and was included in the Hang Seng Shanghai-Shenzhen-Hong Kong Connect Biotechnology 50 Index and Hang Seng China (Hong Kong Listed) 25 Index in 2020. Sino Biopharm has consistently ranked among the "Top 50 Global Pharmaceutical Companies" by the authoritative U.S. magazine *Pharm Exec* for five consecutive years and has been recognized as one of the "Top 50 Best Asia-Pacific Companies" by *Forbes* (Asia) for three consecutive years. Sino Biopharm’s enterprises are located in Beijing, Shanghai, Nanjing, Lianyungang, Qingdao, and other regions, with multiple pharmaceutical production bases. Since its establishment, the company has achieved remarkable accomplishments and maintained steady growth. Core enterprises such as Zhengda Tianqing Pharmaceutical Group and Beijing Tide Pharmaceutical Co., Ltd. have consistently ranked among the top 100 pharmaceutical industrial enterprises in China. With generics as its foundation, the company is transitioning comprehensively toward innovation, with innovative drugs driving growth and their revenue share increasing year by year. Internal R&D pipelines are fueling this innovative transformation while continuously enhancing technological platforms. Under the leadership of top-tier scientific teams, the company is actively promoting internationalization and securing a position at the forefront of global advancements. Sino Biopharm will adhere to its mission of “Health Technology, Warming More Lives,” focus on innovation, serve patients, and strive to become a globally leading pharmaceutical enterprise. We look forward to sharing the development achievements of the pharmaceutical and healthcare industry with like-minded individuals and working together for mutual success!